According to Zacks, “Trupanion, Inc. operates as a direct-to-consumer monthly subscription service provider of a medical insurance plan for cats and dogs. It operates primarily in Canada, Puerto Rico, and the United States. The Company serves pet owners and veterinarians. Trupanion, Inc. is headquartered in Seattle, Washington. “
Other equities analysts also recently issued research reports about the company. BidaskClub raised Trupanion from a hold rating to a buy rating in a research report on Wednesday, January 2nd. ValuEngine raised Trupanion from a hold rating to a buy rating in a research report on Thursday, March 21st. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $45.50.
Trupanion (NASDAQ:TRUP) last posted its earnings results on Wednesday, February 13th. The financial services provider reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.02). Trupanion had a negative net margin of 0.30% and a negative return on equity of 0.88%. The firm had revenue of $82.64 million during the quarter, compared to analyst estimates of $82.16 million. The firm’s revenue for the quarter was up 24.2% compared to the same quarter last year. On average, analysts anticipate that Trupanion will post 0.09 EPS for the current year.
In related news, CEO Darryl Rawlings sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $28.45, for a total value of $113,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,551,421 shares in the company, valued at $44,137,927.45. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Asher Bearman sold 10,300 shares of the business’s stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $32.58, for a total value of $335,574.00. Following the completion of the sale, the insider now owns 8,191 shares of the company’s stock, valued at $266,862.78. The disclosure for this sale can be found here. Over the last quarter, insiders sold 167,286 shares of company stock valued at $5,053,483. 20.70% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of TRUP. Catalyst Capital Advisors LLC bought a new stake in shares of Trupanion in the fourth quarter valued at approximately $59,000. Citigroup Inc. boosted its stake in shares of Trupanion by 12,818.2% in the fourth quarter. Citigroup Inc. now owns 2,842 shares of the financial services provider’s stock valued at $72,000 after buying an additional 2,820 shares during the period. Great West Life Assurance Co. Can boosted its stake in shares of Trupanion by 105.1% in the fourth quarter. Great West Life Assurance Co. Can now owns 3,691 shares of the financial services provider’s stock valued at $91,000 after buying an additional 1,891 shares during the period. Resources Investment Advisors Inc. bought a new stake in Trupanion during the fourth quarter worth $102,000. Finally, Legal & General Group Plc lifted its stake in Trupanion by 14.9% during the fourth quarter. Legal & General Group Plc now owns 4,552 shares of the financial services provider’s stock worth $116,000 after purchasing an additional 590 shares during the last quarter. Institutional investors and hedge funds own 97.13% of the company’s stock.
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, and Puerto Rico. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians through third-party referrals and online member acquisition channels.
Recommended Story: What is a support level?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.